ArticlePharmacoEconomics2021

Cost Effectiveness of Ribociclib in Combination with Fulvestrant for the Treatment of Postmenopausal Women with HR+/HER2- Advanced Breast Cancer Who Have Received No or Only One Prior Line of Endocrine Therapy: A Canadian Healthcare Perspective.

Daniel Stellato et al.PubMed ↗Publisher ↗

No numbers read from the abstract.